TAK-994 mechanistic investigation into drug-induced liver injury
Toxicological Sciences · 01.04.2025 · 204 (2) · 143-153
DOI: 10.1093/toxsci/kfaf003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 09.01.2025. Verfasst von Tadahiro Shinozawa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceutical Company Ltd, Fujisawa, Kanagawa 251-8555, Japan. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Hepatocytes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc..
Abstract (Originalsprache)
The frequency of drug-induced liver injury (DILI) in clinical trials remains a challenge for drug developers despite advances in human hepatotoxicity models and improvements in reducing liver-related attrition in preclinical species. TAK-994, an oral orexin receptor 2 agonist, was withdrawn from phase II clinical trials due to the appearance of severe DILI. Here, we investigate the likely mechanism of TAK-994 DILI in hepatic cell culture systems examined cytotoxicity, mitochondrial toxicity, impact on drug transporter proteins, and covalent binding. Hepatic liabilities were absent in rat and nonhuman primate safety studies, however, murine studies initiated during clinical trials revealed hepatic single-cell necrosis following cytochrome P450 induction at clinically relevant doses. Hepatic cell culture experiments uncovered wide margins to known mechanisms of intrinsic DILI, including cytotoxicity (>100× Cmax/IC50), mitochondrial toxicity (>100× Cmax/IC50), and bile salt efflux pump inhibition (>20× Css, avg/IC50). A potential covalent binding liability was uncovered with TAK-994 following hepatic metabolism consistent with idiosyncratic DILI and the delayed-onset clinical toxicity. Although idiosyncratic DILI is challenging to detect preclinically, reductions in total daily dose and covalent binding can reduce the covalent body binding burden and, subsequently, the clinical incidence of idiosyncratic DILI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Takeda Pharmaceutical Company Ltd, Fujisawa, Kanagawa 251-8555, Japan.
- Takeda Development Center Americas, Inc, Cambridge, MA 02139, United States.
- Takeda Development Center Americas, Inc, San Diego, CA 92121, United States.
- Clarivate, 398 08025 Barcelona, Spain.
- Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 3M2, Canada.
ORCID-Profile: Kimio Tohyama
Förderung
- Takeda Development Center Americas, Inc.
Zitieren
APA
Shinozawa, T., Miyamoto, K., Baker, K. S., Faber, S. C., Flores, R., Uetrecht, J., von Hehn, C., Yukawa, T., Tohyama, K., Kadali, H., von Grotthuss, M., Sudo, Y., Smith, E. N., Diogo, D., Zhu, A. Z. X., Dragan, Y., Cebers, G., & Wagoner, M. P. (2025). TAK-994 mechanistic investigation into drug-induced liver injury. Toxicological Sciences, 204(2), 143-153. https://doi.org/10.1093/toxsci/kfaf003
Vancouver
Shinozawa T, Miyamoto K, Baker KS, Faber SC, Flores R, Uetrecht J, et al. TAK-994 mechanistic investigation into drug-induced liver injury. Toxicological Sciences. 2025;204(2):143-153. doi:10.1093/toxsci/kfaf003
BibTeX
@article{Shinozawa2025,
author = {Shinozawa, Tadahiro and Miyamoto, Kazumasa and Baker, Kevin S and Faber, Samantha C and Flores, Ramon and Uetrecht, Jack and von Hehn, Christian and Yukawa, Tomoya and Tohyama, Kimio and Kadali, Harisha and von Grotthuss, Marcin and Sudo, Yusuke and Smith, Erin N and Diogo, Dorothée and Zhu, Andy Z X and Dragan, Yvonne and Cebers, Gvido and Wagoner, Matthew P},
title = {TAK-994 mechanistic investigation into drug-induced liver injury},
journal = {Toxicological Sciences},
year = {2025},
volume = {204},
number = {2},
pages = {143--153},
doi = {10.1093/toxsci/kfaf003}
}
EUVIMED